Associations of Gut and Circulating Microbiota with Circulating Vitamin D3, Type I Interferon, and Systemic Inflammation in Chronic Spontaneous Urticaria Patients
DOI: https://doi.org/10.2147/jir.s455489
IF: 4.5
2024-05-06
Journal of Inflammation Research
Abstract:Zhi Yang, 1 Yao Song, 1 Bangtao Chen, 2 Fei Hao 1 1 Department of Dermatology, Third Affiliated Hospital of Chongqing Medical University, Chongqing, 401120, People's Republic of China; 2 Department of Dermatology, Chongqing University Three Gorges Hospital, School of Medicine, Chongqing University, Chongqing, 404100, People's Republic of China Correspondence: Bangtao Chen; Fei Hao, Email ; Objective: To analyze the associations of the gut and circulating microbiota with circulating vitamin D 3 (VD3), type I interferon (IFNI), systemic inflammation, and clinical profiles in chronic spontaneous urticaria (CSU) patients. Methods: A total of 36 CSU patients with VD3 insufficiency (VDI; serum 25(OH)VD3 < 30 ng/mL) and 36 sex-, age-, and body mass index–matched CSU patients with non-VDI were enrolled. Fecal and serum bacteria were identified through 16S rRNA sequencing, and serum 25(OH)VD3 and inflammation biomarkers were assessed using ELISA kits. IFNI response was determined by measuring the stimulatory activity of serum on IFNI-stimulated response element in HEK293 cells in vitro with luciferase assays. Results: Higher urticarial activity score over 7 days (UAS7), higher frequency of levocetirizine resistance, and more severe proinflammation but weaker IFNI response were observed in VDI than non-VDI patients (all P < 0.05). IFNI response was strongly positively associated with serum 25(OH)VD3 level in both groups ( P < 0.001). Compared to non-VDI patients, abundance of the fecal genera Prevotella 9, Escherichia–Shigella , and Klebsiella was significantly increased, while Bacteroides , Faecalibacterium , and Agathobacter were remarkably reduced in VDI patients (all P < 0.05). Burkholderia – Caballeronia–Paraburkholderia (40.95%), Acinetobacter (3.05%), and Aquabacterium (2.37%) were the top three bacteria in sera from VDI patients. Both serum 25(OH)VD3 level and IFNI response were positively associated with fecal Bacteroides in the two groups ( P < 0.05). In non-VDI patients, there were moderately positive associations between IFNI response and fecal Lachnoclostridium , unclassified_f__Lachnospiraceae, and Phascolarctobacterium and between serum 25(OH)VD3 level and fecal Lachnoclostridium (all P < 0.01). Circulating microbiota in VDI patients was closely related only to proinflammation and UAS7 (both P < 0.05). Conclusion: Changes in gut but not circulating microbiota composition are associated with serum 25(OH)VD3 insufficiency and impaired IFNI homeostasis, which points to greater disease severity (UAS7) and systemic proinflammation in CSU patients. Keywords: chronic spontaneous urticaria, microbiota, vitamin D 3 , type I interferon, inflammation Chronic spontaneous urticaria (CSU), a clinical subtype that accounts for about two thirds of cases of chronic urticaria, is generally regarded as a debilitating skin disorder characterized by recurrent episodes of intensely pruritic wheals with or without associated angioedema persisting ≥6 weeks. Although affecting up to 0.67% of the global population at some point during life, it is obviously self-limiting. 1 However, CSU patients still come to dermatology departments seeking help for the intolerable itching that significantly impairs sleep and daily activities. Regrettably, up to 40%–60% of patients receiving first-line treatment (second-generation nonsedating H 1 antihistamines [nsAHs] at licensed doses) still require higher doses of nsAHs or other approaches, including glucocorticoids, cyclosporine, or biologics, which inevitably brings substantial financial burden and drug-safety concerns for them. 2 The release of histamine and other inflammatory mediators upon mast-cell activation is widely recognized as central to CSU pathophysiology. We and others have shown that CSU is also involved other systemic abnormalities, including autoimmunity, imbalance of T h 1/T h 2/T h 17 cytokines, enteric dysbacteriosis, abnormal activation of the coagulation system, and vitamin D 3 (VD3) insufficiency (VDI). 3,4 Noteworthily, the above abnormalities may not concurrently present in one CSU patient, though one of them may predominate. Data concerning serum 25(OH)VD3 concentration and partial clinical benefit in CSU with VD3 supplementation indicate a need for dermatologists to focus on the possible causation and regulating effects of VD3 in the heterogeneity of CSU pathogenesis. 5 To better manage this frustrating disease with VD3, efforts to -Abstract Truncated-
immunology